


10. Process for the preparation of compounds of the formula I according to Claims 1-9 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, characterised in that a compound of the formula II

5




in which X and Y have the meanings indicated in Claim 1,

10

is reacted

with a compound of formula III

15



in which W has the meanings indicated in Claim 1,

and L denotes Cl, Br, I or a free or reactively functionally modified OH group,

20

and/or

a base or acid of the formula I is converted into one of its salts.

25

11. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally an pharmaceutically acceptable carrier, excipient or vehicle.


30

12. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

35

13. Set (kit) consisting of separate packs of
- (a) an effective amount of a compound of the formula I and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and
- (b) an effective amount of a further medicament active ingredient.

14. The compound
3-{4-[3-(4-Methoxy-benzoyl)-azetidin-1-yl]-4-oxo-butyl}-2H-pyrrolo[1,2-a]pyrazin-1-one ("D1")



and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.